In recent years, the relationship between the intestine and diseases of other parts of the human body has received increasing attention from the medical community. In an article in the new issue of the Journal of Biochemistry, scientists mentioned that a bacterium in the human gut may reduce the risk of heart disease.
The article writes that the intestine produces a chemical substance that enters the blood and then into the liver, where it is converted into substances related to arterial occlusion. And also in the intestine, there is a “good bacteria” that will reduce the production of this chemical.
The researchers believe that this good bacterium can be traced back to a protein family, which may also explain the contribution of other intestinal flora to human health. Essentially, these microbes compete with bad bacteria for the same nutrients in the intestine. If good bacteria win, they may prevent health problems caused by the body’s metabolism of food.
Scientists believe that this gut microbe may be used for treatment in the future.
“Over the past 10 years, the understanding of human gut bacteria in many ways affecting health has become increasingly clear,” said Joseph Krzycki, a professor of microbiology at Ohio State University and senior author of the study.
Consistent with what he said, studying the impact of the intestine on human health is a trend in the medical community in recent years.
For example, in April of this year, “Nature” published a breakthrough study on Parkinson’s disease, saying that the disease is caused by the accumulation of misfolded proteins called Lewy bodies. An animal study last year showed that these toxic proteins first accumulated in the intestine, then moved up to the brain through the vagus nerve, and subsequently caused the death of neurons that secrete dopamine in the brain, resulting in movement disorders and other common symptoms.
Earlier in January, the article published in Cell Report also focused on gut bacteria. Studies say that a probiotic called Bacillus subtilis in the intestine can produce certain chemicals. This chemical can not only prevent the formation of α-synuclein, the main component of Lewy body, but also remove some protein clumps that have formed.
At the end of last year, University of Florida researchers received a US$500,000 grant from the US Department of Agriculture to study whether orange peel extract can improve the ability of the intestine to prevent the formation of lining fat in arteries. The basis of this research is also based on the study of intestinal microbiota.
The research team hypothesized that orange peel extract could change the gut microbiota and prevent atherosclerosis, and they did achieve some results in mouse experiments.
Of course, the most famous recent research on intestinal flora and diseases is the Alzheimer’s disease drug launched in China last year, “Nine Phase One.” This is a new drug that claims to “end 17 years of global history of no new drugs in this field.” This drug is the world’s first drug targeting Alzheimer’s disease of the brain-gut axis, which is to treat the intestinal flora to treat Alzheimer’s disease.
Before the drug became available, doubts about the authenticity of its test data continued. On November 28 last year, the letter signed by the president of the Capital Medical University “Rao Yi” pointed directly to academic fraud in related research, and its new specifications have not yet been approved by the FDA. A few days ago, Rao Yi once again issued a “bombardment”, thinking that the authenticity of the paper published by the research team in the top journal “Cell Research” in October 2019 is worrying.